US Food and Drug Administration (FDA) has approved mNEXSPIKE (mRNA-1283), a new vaccine against Covid-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Investor sentiment toward Moderna Inc. turned sour during the weekend, despite obtaining FDA authorization for its newest ...